688247 宣泰医药
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入331,465-8.59%511,619299,871247,562315,471
减:营业总成本276,5223.78%384,024245,992183,423221,940
    其中:营业成本196,18210.95%247,467132,26571,22669,001
               财务费用(1,710)-49.49%(6,330)(7,241)(8,497)2,820
               资产减值损失(865)-804.60%1,622(1,532)2,586(1,043)
公允价值变动收益----------457
投资收益9,18231.26%12,04511,36921,7804,178
    其中:对联营企业和合营企业的投资收益2,4391,201.58%562(2,138)4,427(706)
营业利润69,568-32.31%143,88069,01299,132121,313
利润总额69,298-32.02%142,08265,99197,475149,013
减:所得税费用5,835-37.69%14,3824,9174,54414,097
净利润63,462-31.45%127,70161,07492,932134,916
减:非控股权益------------
股东净利润63,462-31.45%127,70161,07492,932134,916

市场价值指针
每股收益 (元) *0.140-33.33%0.2800.1300.2200.330
每股派息 (元) *0.0250.00%0.0620.0410.062--
每股净资产 (元) *2.8855.73%2.8082.6702.5971.730
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容